New Breakthrough Treatment for Fatty Liver Disease | Boost NAD+ to Combat MASLD & MASH

A revolutionary new approach to combating fatty liver disease (MASLD) and MASH (Metabolic Dysfunction-Associated Steatohepatitis) is here! Recent research has revealed how boosting NAD+ levels in the liver can reduce inflammation, reverse fibrosis, and protect liver health. This groundbreaking discovery targets a specific enzyme, ACMSD, and has shown promising results in both rodent models and human liver organoids.

With around 25% of the global population affected by MASLD, this study offers new hope for millions suffering from liver damage. In this video, we’ll explore how ACMSD inhibition could revolutionize treatment for liver disease, moving from symptom management to tackling the root cause of metabolic dysfunction.

🔬 Key Insights:

How NAD+ deficiency leads to liver damage and disease progression
The role of ACMSD in liver health
How TLC-065 can reverse liver fibrosis and inflammation
The promise of this new therapy for MASLD and MASH patients
Stay tuned to learn how this breakthrough could reshape the future of liver disease treatment!

📌 Don’t forget to like, subscribe, and click the bell icon for more health breakthroughs!